DUBLIN, Dec. 20, 2013 /PRNewswire/ -- Actavis plc (NYSE:ACT), a leading specialty pharmaceutical company, announced today that Paul Bisaro, Chairman and Chief Executive Officer, will provide an overview and update of the Company's business at the 32nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2014 at 7:30 am PST (10:30 am EST) at the Westin St. Francis Hotel, San Francisco, California.
To access the webcast, go to Actavis' Investor Relations Web site at http://ir.actavis.com. The webcast can also be accessed at the following URL:
http://jpmorgan.metameetings.com/confbook/healthcare14/directlink?ticker=ACT
An archived version will be available approximately one hour after the live presentation ends and can be accessed at the same locations for 90 days.
About Actavis
Actavis plc (NYSE: ACT) is a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products. Actavis has global headquarters in Dublin, Ireland and U.S. administrative headquarters in Parsippany, New Jersey, USA.
Actavis markets generic, branded generic, legacy brands and Over-the-Counter (OTC) products in more than 60 countries, and operates a global branded specialty pharmaceutical business focused in the Women's Health, Urology, Gastroenterology and Dermatology therapeutic categories. Actavis also has a portfolio of five biosimilar products in development in Women's Health and Oncology. Actavis Global Operations has more than 30 manufacturing and distribution facilities around the world, and includes Anda, Inc., a U.S. pharmaceutical product distributor.
For press release and other company information, visit Actavis' Web site at http://www.actavis.com.
CONTACTS: Investors:
Lisa DeFrancesco
(862) 261-7152
Media:
Charlie Mayr
(862) 261-8030
David Belian
(862) 261-8141
(Logo: http://photos.prnewswire.com/prnh/20130124/NY47381LOGO )
SOURCE Actavis plc
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article